45 research outputs found

    White-light photoluminescence and photoactivation in cadmium sulfide embedded in mesoporous silicon dioxide templates studied by confocal laser scanning microscopy

    Get PDF
    This is the author's version of a work that was accepted for publication in Journal of colloid and interface science. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of colloid and interface science, [147, 1, (2013)] DOI10.1016/j.jcis.2013.06.022)SBA-15 and SBA-16 silica templates have been infiltrated with CdS by means of nanocasting using a hybrid precursor. The morphology and structure of both the SiO2@CdS nanocomposites and the silica-free CdS replicas have been characterized. The three-dimensional nanocrystalline CdS networks embedded in SBA-15 and SBA-16 silica templates exhibit broad photoluminescence (PL) spectra over the entire visible range, together with enhanced PL intensity compared to silica-free CdS replicas. These effects result from the role silica plays in passivating the surface of the CdS mesostructures. Furthermore, photoactivation is eventually observed during continuous illumination because of both structural and chemical surface odifications. Owing to this combination of properties, these materials could be appealing for solid-state lighting, where ultra-bright near-white PL emission is indispensable

    Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

    Get PDF
    Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

    Your premature baby : a message to the family /

    No full text
    1st ed. printed in 1947.Important things to keep in mind in caring for the baby -- Protection of the baby from harm -- Using the incubator -- Feeding the baby -- Diapering the baby -- Bathing the baby.Mode of access: Internet.TAUB: bookplate: "Donated in memory of Johan Wijnbladh Eliot, M.D.

    The cost-effectiveness of belimumab and voclosporin for patients with Lupus Nephritis in the United States

    No full text
    Background and objectives: Despite existing therapies, people with lupus nephritis progress to kidney failure and have reduced life expectancy. Belimumab and voclosporin are two new disease-modifying therapies recently approved for the treatment of lupus nephritis. Design, setting, participants, & measurements: A de novo economic model was developed to estimate the cost-effectiveness of these therapies, including the following health states: “complete response,” “partial response,” and “active disease” defined by eGFR and proteinuria changes, kidney failure, and death. Short-term data and mean cohort characteristics were sourced from pivotal clinical trials of belimumab (the Belimumab International Study in Lupus Nephritis) and voclosporin (the Aurinia Urinary Protection Reduction Active–Lupus with Voclosporin trial and Aurinia Renal Response in Active Lupus With Voclosporin). Risk of mortality and kidney failure were on the basis of survival modeling using published Kaplan–Meier data. Each drug was compared with the standard of care as represented by the comparator arm in its respective pivotal trial(s) using US health care sector perspective, with a societal perspective also explored. Results: In the health care perspective probabilistic analysis, the incremental cost-effectiveness ratio for belimumab compared with its control arm was estimated to be approximately 95,000perqualityadjustedlifeyear.Thecorrespondingincrementalratioforvoclosporincomparedwithitscontrolarmwasapproximately95,000 per quality-adjusted life year. The corresponding incremental ratio for voclosporin compared with its control arm was approximately 150,000 per quality-adjusted life year. Compared with their respective standard care arms, the probabilities of belimumab and voclosporin being cost effective at a threshold of 150,000perqualityadjustedlifeyearwere69150,000 per quality-adjusted life year were 69% and 49%, respectively. Cost-effectiveness was dependent on assumptions made regarding survival in response states, costs and utilities in active disease, and the utilities in response states. In the analysis from a societal perspective, the incremental ratio for belimumab was estimated to be approximately 66,000 per quality-adjusted life year, and the incremental ratio for voclosporin was estimated to be approximately 133,000perqualityadjustedlifeyear.Conclusions:Comparedwiththeirrespectivestandardcarearms,belimumabbutnotvoclosporinmetwillingnesstopaythresholdsof133,000 per quality-adjusted life year. Conclusions: Compared with their respective standard care arms, belimumab but not voclosporin met willingness-to-pay thresholds of 100,000 per quality-adjusted life year. Despite potential clinical superiority in the informing trials, there remains high uncertainty around the cost-effectiveness of voclosporin

    Variabilidade genética de búfalos em rebanho-núcleo com base na análise de pedigree Genetic variability in water buffalo from nucleous herd by pedigree analysis

    Get PDF
    Parâmetros baseados na probabilidade de origem do gene foram usados para descrever a variabilidade em uma população de búfalos da Embrapa Amazônia Oriental. A magnitude dos resultados foi de média a baixa (por volta de 20 animais), sugerindo que poucos fundadores contribuiriam para a formação da população. Dentre os 20 ancestrais que mais aportam genes aos machos - representando ao todo 71% dos alelos -, 39%, 26% e 5%, respectivamente, são as contribuições marginais das raças Murrah e Mediterrâneo e seus mestiços. Para as fêmeas, em que os 20 ancestrais aportam 67,5% dos genes, 42% e 26%, respectivamente, são as contribuições marginais das raças Murrah e Mediterrâneo.<br>Parameters based on the probability of gene origin were used to describe genetic variability in a buffalo population from the Embrapa Amazônia Oriental, Belém, Pará, Brazil. The parameters generated medium to low values (around 20 animals) and suggested low founder representativeness. From the 20 ancestors that gave more genes to males (with 71% of alleles), genetic contributions were 39%, 26%, and 5%, respectively, for Murrah, Mediterraneo, and crossbreds. For females, these values were 42% and 26% for Murrah and Mediterraneo breeds
    corecore